Mastocytosis is a proliferative disease of mast cells. Mastocytosis belongs to the Orphan diseases and is listed as such in the Orphanet database. Treatment is not indicated in most cutaneous variants and noncomplicated cases without complaints and/or systemic involvement. In cases with complaints or suspicion of systemic involvement, multidisciplinary approach is indicated.
KeywordsMastocytosis Orphan disease Mastocytoma Cutaneous mastocytosis Diffuse cutaneous mastocytosis Systemic mastocytosis
- Fuller SJ. New insights into pathogenesis, diagnosis and management of mastocytosis. Immunol Allergy Clin N Am. 2012;26:1143–68.Google Scholar
- Gotlib J, George TI. The KIT tyrosine kinase inhibitor midostaurine (PKC412) exhibits a high response rate in Aggressive Systemic Mastocytosis (ASM): interim results of a phase II trial. Blood (ASH Annual Meeting Abstracts). 2007;110:3536.Google Scholar
- Rondoni M, Paolini S. Response to dasatinib in patients with aggressive systemic mastocytosis with D816V Kit mutation. Blood (ASH Annual Meeting Abstracts). 2007;110:3562.Google Scholar
- Verstovsek S, Tefferi A. Phase II study of dasatinib (SPRYCELTM) in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. Blood (ASH Annual Meeting Abstracts). 2007;110:3551.Google Scholar